[
    {
        "pregunta": "1. Why does the panel strongly recommend against the use of TNF-alpha blocking agents in PMR treatment?",
        "respuesta": "El panel recomienda fuertemente no usar agentes bloqueadores del TNF-alfa en el tratamiento de la polimialgia reumática (PMR) porque no existe evidencia que demuestre beneficio, mientras que sí hay un riesgo considerable de daño potencial y un alto consumo de recursos.",
        "contexto": [
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "but put considerations of quality of evidence for benefit over other considerations. This guideline provides recommendations for early and aggressive therapy in patients with newly diagnosed PsA. The recommendation is, however, conditional, and the panel recognized several potential exceptions to it. Circumstances in which a patient may choose an OSM over a TNFi biologic may include mild-to-moderate disease, a preference of oral over parenteral therapy, or concerns regarding adverse effects of a biologic. A TNFi biologic would not be a good choice in patients with contraindications, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease. During the development of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recommendations In patients with concomitant IBD, the Voting Panel made strong recommendations favoring a monoclonal antibody TNFi or an IL-12/23i biologic over an IL-17i biologic or a TNFi",
            "over alternative agents when oral dosing is not possible. In patients experiencing an inadequate response to an initial agent, the Voting Panel cited insufficient evidence to make specific recommendations regarding subsequent antiinflammatory agents to use. If a patient is unable to tolerate or has contraindications to any of the other conventional alternatives, the Voting Panel conditionally recommended the use of IL-1 inhibitors , recognizing concerns over patient access due to cost. Noting limited supporting data Underscoring the importance of optimal flare management, the Patient Panel emphasized its preference for early intervention given the challenges of engaging a provider in timely manner, including an at-home \"medication-in-pocket\" strategy for patients who are able to identify the early signs of flare onset. In the absence of \"rapid\" access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances",
            "<h1>Table 3. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with a TNFi biologic, as monotherapy or in combination with MTX (PICOs 26–35; 70–75)*</h1>"
        ]
    },
    {
        "pregunta": "2. How should glucocorticoid doses be tapered in PMR patients, according to current clinical practice recommendations?",
        "respuesta": "Según las recomendaciones clínicas actuales, la reducción (tapering) de glucocorticoides (GC) en pacientes con polimialgia reumática (PMR) debe realizarse cuidadosamente cuando el paciente esté en baja actividad de la enfermedad o en remisión. Aunque existe escasez de datos específicos sobre el mejor momento y modo para disminuir la dosis, se sugiere:\n\n- Ajustar la reducción de GC según la respuesta clínica, considerando la manifestación de síntomas.  \n- Evaluar estrechamente al paciente durante el proceso; si ocurre una recaída, se debe reestablecer la dosis previa de glucocorticoides.  \n- Considerar dosis bajas únicas diarias de GC en lugar de dosis divididas, salvo en situaciones especiales como dolor nocturno prominente al bajar por debajo de 5 mg diarios de prednisona o equivalente. En estos casos, puede evaluarse dividir la dosis.\n\nEn resumen, la pauta de disminución debe ser individualizada, gradual y basada en la actividad clínica, con monitoreo frecuente para evitar recaídas.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when and how best to taper. The panel recommended that careful tapering might be considered if the patient wishes to cut back on their use of DMARDs. However, patients should be closely evaluated during any taper, and if a flare occurs, the prior regimen should be reinstituted promptly. Last, this update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision",
            "The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical practice this preparation may be considered in cases where a lower cumulative GC dose is desirable, for example in female patients with difficult to control hypertension, diabetes, osteoporosis and/or glaucoma The reasons why the panel did not endorse a strong recommendation for the use of i.m. methylprednisolone are the following: 1) the efficacy of i.m. methylprednisolone is supported by a single randomized controlled trial and confirmation of these data is still necessary Recommendation 6: (PICO 8) The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on",
            "below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on clinical experience and because of the concern that adverse events (including disturbance of the hypothalamic-pituitary-adrenal axis) may be higher with divided doses, the group agreed against the general use of divided GC doses in PMR In special situations such as in case of night pain while tapering below the low-dose range (prednisone or equivalent ,5 mg daily), split doses may be considered. However, persistent breakthrough symptoms should prompt re-consideration of the diagnosis. Recommendation 7: (PICO 9) The panel conditionally recommends considering early introduction of MTX in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy as well as in cases with risk factors, comorbidities and/or concomitant medications where GC-related adverse events are more likely to occur. MTX may also be",
            "research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa biologic, conventional synthetic and conventional targeted) in PMR? What is the optimal strategy for using DMARDs in PMR: monotherapy versus combination therapy, early versus late introduction, and (particularly for biologics) use with or without GCs? 4. What is the minimal/optimal duration of therapy and which strategies for withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including"
        ]
    },
    {
        "pregunta": "3. How should patients with long-standing PMR on low-dose glucocorticoids be managed according to the guideline?",
        "respuesta": "Según las recomendaciones clínicas actuales, en pacientes con polimialgia reumática (PMR) de larga evolución que están en dosis bajas de glucocorticoides (GC), el manejo debe centrarse en una reducción cuidadosa y gradual de la dosis, siempre que el paciente esté en baja actividad o remisión de la enfermedad. Esto incluye:\n\n- Considerar la disminución progresiva de GC ajustando la dosis según la respuesta clínica y los síntomas presentes.  \n- Supervisar estrechamente al paciente durante la reducción para detectar recaídas; en caso de que ocurran, se debe reestablecer la dosis previa de glucocorticoides para controlar la enfermedad.  \n- Evaluar la posibilidad de administrar la dosis baja de GC en toma única diaria, a menos que exista dolor nocturno significativo cuando la dosis sea inferior a 5 mg diarios de prednisona o equivalente, en cuyo caso se puede valorar dividir la dosis.\n\nAdemás, puede considerarse la disminución o suspensión de medicamentos modificadores de la enfermedad (DMARDs) si el paciente está estable, pero bajo estricto control clínico.\n\nEn resumen, la guía aconseja un manejo individualizado con tapering lento y vigilancia estrecha para evitar recaídas y minimizar el uso prolongado de glucocorticoides, debido al riesgo de efectos adversos a largo plazo.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when and how best to taper. The panel recommended that careful tapering might be considered if the patient wishes to cut back on their use of DMARDs. However, patients should be closely evaluated during any taper, and if a flare occurs, the prior regimen should be reinstituted promptly. Last, this update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision",
            "patients may benefit from continuing remission maintenance therapy for a longer duration Ungraded position statement: The duration of glucocorticoid therapy for GPA/MPA should be guided by the patient's clinical condition, preferences, and values. The optimal duration of glucocorticoid therapy for GPA/MPA is not well established. The immunosuppressive effects of glucocorticoids contributing to disease control should be balanced with the toxicities associated with its use. Overall, patients expressed a desire to minimize the glucocorticoid dose as much as possible but recognized that some patients may require low-dose glucocorticoids long-term to maintain disease quiescence. Screening for toxicities of glucocorticoid use (e.g., bone mineral density testing for osteoporosis) should be conducted. Treatment of disease relapse Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance,",
            "and results from small studies Ungraded position statement: The duration of glucocorticoid therapy in EGPA should be guided by the patient's clinical condition, values, and preferences. There is insufficient published evidence to support a specific duration of glucocorticoid treatment, and thus, the length of glucocorticoid therapy should be determined based on each patient's clinical circumstances. Many patients with EGPA require some treatment with glucocorticoids, generally at a low dose, to maintain control of asthma and allergy symptoms. The minimum effective dose should be prescribed to minimize glucocorticoid toxicity. Treatment of disease relapse Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with cyclophosphamide, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction. Rituximab is favored based on the general desire to avoid",
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints"
        ]
    },
    {
        "pregunta": "4. Why does the panel recommend single daily dosing of oral glucocorticoids over divided doses in PMR patients?",
        "respuesta": "El panel recomienda condicionalmente la administración de glucocorticoides orales en dosis única diaria en lugar de dosis divididas en pacientes con polimialgia reumática (PMR) basándose en la experiencia clínica y las preocupaciones sobre que las dosis divididas podrían aumentar el riesgo de efectos adversos, incluyendo la alteración del eje hipotálamo-hipófisis-adrenal. \n\nNo existen estudios específicos en PMR que aborden directamente esta cuestión, pero el grupo acordó evitar el uso generalizado de dosis divididas por dichas razones. Solo en situaciones especiales, como dolor nocturno prominente al reducir la dosis por debajo de 5 mg diarios de prednisona o equivalente, se puede considerar dividir la dosis.\n\nEn resumen, la preferencia por dosis única diaria se fundamenta en minimizar efectos adversos potenciales y la práctica clínica, con excepción de casos con síntomas nocturnos importantes.",
        "contexto": [
            "The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical practice this preparation may be considered in cases where a lower cumulative GC dose is desirable, for example in female patients with difficult to control hypertension, diabetes, osteoporosis and/or glaucoma The reasons why the panel did not endorse a strong recommendation for the use of i.m. methylprednisolone are the following: 1) the efficacy of i.m. methylprednisolone is supported by a single randomized controlled trial and confirmation of these data is still necessary Recommendation 6: (PICO 8) The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on clinical experience and because of the concern that adverse events (including disturbance of the hypothalamic-pituitary-adrenal axis) may be higher with divided doses, the group agreed against the general use of divided GC doses in PMR In special situations such as in case of night pain while tapering below the low-dose range (prednisone or equivalent ,5 mg daily), split doses may be considered. However, persistent breakthrough symptoms should prompt re-consideration of the diagnosis. Recommendation 7: (PICO 9) The panel conditionally recommends considering early introduction of MTX in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy as well as in cases with risk factors, comorbidities and/or concomitant medications where GC-related adverse events are more likely to occur. MTX may also be",
            "this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when and how best to taper. The panel recommended that careful tapering might be considered if the patient wishes to cut back on their use of DMARDs. However, patients should be closely evaluated during any taper, and if a flare occurs, the prior regimen should be reinstituted promptly. Last, this update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision",
            "adverse events. The group further agreed that MTX may be used with oral or i.m. GC preparations even if the concomitant use of MTX and i.m. methylprednisolone has not been tested formally. The efficacy of MTX was addressed in four randomized controlled trials and one retrospective study testing the use of MTX plus oral GCs (initial prednisone doses ranging from 15 to 25 mg/day) The reasons why the panel did not support a stronger recommendation for the use of MTX in PMR are the following: 1) the total number of patients investigated in randomized trials was small (n5194) The group recognized that no recommendation can be made for the use of other non-biologic (ie, conventional synthetic and conventional targeted) DMARDs in PMR because of the lack of good evidence from PMR studies. Hydroxychloroquine was investigated by a single very low QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of"
        ]
    },
    {
        "pregunta": "5. How has the systematic literature review approach influenced the scope of the recommendations for PMR?",
        "respuesta": "El enfoque riguroso de la revisión sistemática de la literatura (SLR) en la elaboración de las recomendaciones para la polimialgia reumática (PMR) ha influido significativamente en el alcance de dichas recomendaciones, ya que:\n\n- Se basó en la selección de estudios de alta calidad, lo que limitó la inclusión de evidencia disponible, dado que hay una escasez de ensayos clínicos robustos sobre PMR.  \n- No se consideraron otras fuentes menos rigurosas, como revisiones previas, reportes de casos o series de casos, que podrían sugerir opciones adicionales, especialmente para pacientes con PMR resistente al tratamiento.  \n- Como resultado, las recomendaciones derivadas están parcialmente respaldadas por evidencia directa y deben considerarse principalmente como consejos clínicos con un fuerte componente de opinión experta y consenso.  \n- Esta limitación llevó a que las recomendaciones no cubran todos los aspectos importantes en el manejo de la PMR y a que el grupo considerara fundamental la creación de una agenda de investigación para cubrir las lagunas de evidencia identificadas.\n\nEn suma, el enfoque estricto de la revisión sistemática proporcionó una base sólida pero limitada para las recomendaciones, restringiendo su alcance a lo que está sólidamente probado y subrayando la necesidad de más investigación en PMR.",
        "contexto": [
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "evidence for benefit is unclear; 4) these preparations may have unforeseeable adverse effects; 5) the availability of high quality preparations is unclear; and 6) resource impact (ie, costs) is unknown. Release and implementation of the recommendations. See online supplementary file S2, on the Arthritis & Rheumatology web site at http://onlinelibrary Cost implications and conflicts of interest. Cost implications are outside the scope of these recommendations. None of the panel members disclosed any conflict of interest associated with the development of these recommendations. Discussion See online supplementary file S3 ( http://online We recognize that our recommendations are only partially supported by evidence, and that they do not cover all aspects important for the management of PMR. The group therefore unanimously agreed that the research agenda (containing the evidence gaps related to PMR management) is an important result of this project (Box 2). Due to our rigorous SLR",
            "the research agenda (containing the evidence gaps related to PMR management) is an important result of this project (Box 2). Due to our rigorous SLR approach to select high quality papers, we did not include other reviews, case reports or case series indicating possible treatment options in treatment-resistant PMR patients. For example, we found one earlier SLR reporting similar conclusions regarding the value of MTX in PMR It was beyond the scope of this recommendation project to define treatment targets in PMR. \"Clinical improvement\" was considered as the first treatment goal after the initiation of GCs, and the response criteria used in the 2012 classification criteria study may be considered The most important limitations of this project are the paucity of high quality trials (as mentioned above) and the fact that GRADE is less well developed for the assessment of rare outcomes. Consequently, the QoE for   Supported by research grants from the American College of Rheumatology",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate"
        ]
    },
    {
        "pregunta": "6. What is the recommended initial daily dose range of prednisone equivalent for the treatment of PMR?",
        "respuesta": "El panel recomienda condicionalmente una dosis diaria inicial de glucocorticoides en el rango de **12.5 a 25 mg de prednisona equivalente** para el tratamiento de la polimialgia reumática (PMR). \n\nDentro de este rango, se puede considerar una dosis inicial más alta (cercana a 25 mg) en pacientes con alto riesgo de recaída y bajo riesgo de efectos adversos, mientras que en pacientes con comorbilidades relevantes (como diabetes, osteoporosis, glaucoma) y otros factores de riesgo para efectos secundarios relacionados con glucocorticoides, se prefiere una dosis inicial más baja (próxima a 12.5 mg). \n\nAdemás, el panel desaconseja condicionalmente el uso de dosis iniciales ≤7.5 mg/día y recomienda fuertemente no usar dosis superiores a 30 mg/día.",
        "contexto": [
            "evidence on this issue. On a basis of consensus and in accordance with the overarching principles, the group unanimously agreed to choose the minimum effective individualized duration and dose of GCs to balance benefit versus harm after assessing risk factors for GC-related adverse events, comorbidities, concomitant medications, relapses and prolonged therapy. Our recommended GC tapering schedule (see Recommendation 4) assumes a minimum of 12 months of treatment. A more specific statement is not possible because of the lack of PMR studies on this particular topic and because of the multiple subgroups and factors that need to be taken into account. Recommendation 3: (PICOs 3-5) The panel conditionally recommends using the minimum effective GC dose within a range of 12.5-25 mg prednisone equivalent daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in",
            "higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in patients with relevant comorbidities (eg, diabetes, osteoporosis, glaucoma, etc.) and other risk factors for GC-related side effects, a lower dose may be preferred. The panel discourages conditionally the use of initial doses #7.5 mg/day and strongly recommends against the use of initial doses .30 mg/day. According to the SLR on prognostic factors and based on clinical experience, the group agreed upon the existence of various PMR subgroups that are characterized by different risks of relapse, prolonged GC therapy and/or GC-related adverse events as well as by various comorbidities and co-medications. As there are insufficient data to make evidence-based recommendations for all conceivable subgroups, and taking current clinical practice into account The group conditionally discourages low (#7.5 mg/ day) and strongly recommends against",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical practice this preparation may be considered in cases where a lower cumulative GC dose is desirable, for example in female patients with difficult to control hypertension, diabetes, osteoporosis and/or glaucoma The reasons why the panel did not endorse a strong recommendation for the use of i.m. methylprednisolone are the following: 1) the efficacy of i.m. methylprednisolone is supported by a single randomized controlled trial and confirmation of these data is still necessary Recommendation 6: (PICO 8) The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on",
            "below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on clinical experience and because of the concern that adverse events (including disturbance of the hypothalamic-pituitary-adrenal axis) may be higher with divided doses, the group agreed against the general use of divided GC doses in PMR In special situations such as in case of night pain while tapering below the low-dose range (prednisone or equivalent ,5 mg daily), split doses may be considered. However, persistent breakthrough symptoms should prompt re-consideration of the diagnosis. Recommendation 7: (PICO 9) The panel conditionally recommends considering early introduction of MTX in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy as well as in cases with risk factors, comorbidities and/or concomitant medications where GC-related adverse events are more likely to occur. MTX may also be"
        ]
    },
    {
        "pregunta": "7. How do cost implications factor into the current PMR treatment recommendations?",
        "respuesta": "La información proporcionada indica que las **implicaciones de costo están fuera del alcance de las recomendaciones actuales para el tratamiento de la polimialgia reumática (PMR)**. No se ofrecen datos ni análisis específicos respecto al impacto económico o al costo-efectividad de las intervenciones recomendadas.  \n\nPor lo tanto, **no hay información suficiente disponible en estas guías para evaluar cómo influyen los costos en la formulación de las recomendaciones para PMR**.",
        "contexto": [
            "evidence for benefit is unclear; 4) these preparations may have unforeseeable adverse effects; 5) the availability of high quality preparations is unclear; and 6) resource impact (ie, costs) is unknown. Release and implementation of the recommendations. See online supplementary file S2, on the Arthritis & Rheumatology web site at http://onlinelibrary Cost implications and conflicts of interest. Cost implications are outside the scope of these recommendations. None of the panel members disclosed any conflict of interest associated with the development of these recommendations. Discussion See online supplementary file S3 ( http://online We recognize that our recommendations are only partially supported by evidence, and that they do not cover all aspects important for the management of PMR. The group therefore unanimously agreed that the research agenda (containing the evidence gaps related to PMR management) is an important result of this project (Box 2). Due to our rigorous SLR",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for"
        ]
    },
    {
        "pregunta": "8. Which patient populations might particularly benefit from methotrexate addition to glucocorticoid therapy in PMR?",
        "respuesta": "Los grupos de pacientes con polimialgia reumática (PMR) que podrían beneficiarse especialmente de la adición de metotrexato (MTX) a la terapia con glucocorticoides (GC), según las recomendaciones, son:\n\n- Pacientes con **alto riesgo de recaída**.  \n- Pacientes con probabilidad de **terapia prolongada con glucocorticoides**.  \n- Pacientes que presenten **factores de riesgo, comorbilidades y/o medicaciones concomitantes** que aumenten la probabilidad de efectos adversos relacionados con los glucocorticoides.\n\nSe recomienda considerar la introducción temprana de MTX en estos casos para mejorar el control de la enfermedad y posiblemente reducir la dosis o duración del tratamiento con glucocorticoides.\n\nEsta recomendación es condicional y está basada en evidencia limitada proveniente de pocos ensayos con un número pequeño de pacientes.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?",
            "adverse events. The group further agreed that MTX may be used with oral or i.m. GC preparations even if the concomitant use of MTX and i.m. methylprednisolone has not been tested formally. The efficacy of MTX was addressed in four randomized controlled trials and one retrospective study testing the use of MTX plus oral GCs (initial prednisone doses ranging from 15 to 25 mg/day) The reasons why the panel did not support a stronger recommendation for the use of MTX in PMR are the following: 1) the total number of patients investigated in randomized trials was small (n5194) The group recognized that no recommendation can be made for the use of other non-biologic (ie, conventional synthetic and conventional targeted) DMARDs in PMR because of the lack of good evidence from PMR studies. Hydroxychloroquine was investigated by a single very low QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of",
            "below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on clinical experience and because of the concern that adverse events (including disturbance of the hypothalamic-pituitary-adrenal axis) may be higher with divided doses, the group agreed against the general use of divided GC doses in PMR In special situations such as in case of night pain while tapering below the low-dose range (prednisone or equivalent ,5 mg daily), split doses may be considered. However, persistent breakthrough symptoms should prompt re-consideration of the diagnosis. Recommendation 7: (PICO 9) The panel conditionally recommends considering early introduction of MTX in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy as well as in cases with risk factors, comorbidities and/or concomitant medications where GC-related adverse events are more likely to occur. MTX may also be",
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate"
        ]
    },
    {
        "pregunta": "9. Under what circumstances might a higher initial dose (closer to 25 mg/day) of prednisone be considered in PMR patients?",
        "respuesta": "Se podría considerar una dosis inicial más alta de prednisona (más cercana a 25 mg/día) en pacientes con polimialgia reumática que presentan **alto riesgo de recaída** y **bajo riesgo de efectos adversos relacionados con los glucocorticoides**. \n\nEn estos casos, la dosis inicial elevada puede ayudar a controlar mejor la enfermedad, siempre evaluando individualmente el riesgo-beneficio. Por el contrario, en pacientes con comorbilidades relevantes o factores de riesgo para efectos secundarios, se prefiere una dosis inicial más baja.",
        "contexto": [
            "higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in patients with relevant comorbidities (eg, diabetes, osteoporosis, glaucoma, etc.) and other risk factors for GC-related side effects, a lower dose may be preferred. The panel discourages conditionally the use of initial doses #7.5 mg/day and strongly recommends against the use of initial doses .30 mg/day. According to the SLR on prognostic factors and based on clinical experience, the group agreed upon the existence of various PMR subgroups that are characterized by different risks of relapse, prolonged GC therapy and/or GC-related adverse events as well as by various comorbidities and co-medications. As there are insufficient data to make evidence-based recommendations for all conceivable subgroups, and taking current clinical practice into account The group conditionally discourages low (#7.5 mg/ day) and strongly recommends against",
            "and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally recommend pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper to a target dose of ≤5mg/day by 6 months. … Who have achieved/sustained a complete renal response after treatment with any (triple or dual) immunosuppressive therapy, we conditionally recommend a total duration of therapy of at least 3-5 years. IN PEOPLE WITH ACTIVE IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF PURE CLASS V: …With",
            "The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical practice this preparation may be considered in cases where a lower cumulative GC dose is desirable, for example in female patients with difficult to control hypertension, diabetes, osteoporosis and/or glaucoma The reasons why the panel did not endorse a strong recommendation for the use of i.m. methylprednisolone are the following: 1) the efficacy of i.m. methylprednisolone is supported by a single randomized controlled trial and confirmation of these data is still necessary Recommendation 6: (PICO 8) The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on",
            "below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on clinical experience and because of the concern that adverse events (including disturbance of the hypothalamic-pituitary-adrenal axis) may be higher with divided doses, the group agreed against the general use of divided GC doses in PMR In special situations such as in case of night pain while tapering below the low-dose range (prednisone or equivalent ,5 mg daily), split doses may be considered. However, persistent breakthrough symptoms should prompt re-consideration of the diagnosis. Recommendation 7: (PICO 9) The panel conditionally recommends considering early introduction of MTX in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy as well as in cases with risk factors, comorbidities and/or concomitant medications where GC-related adverse events are more likely to occur. MTX may also be",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on"
        ]
    },
    {
        "pregunta": "10. What are the implications of the lack of consensus on glucocorticoid dosing and tapering strategies for PMR management?",
        "respuesta": "Las implicaciones de la falta de consenso sobre las dosis iniciales y las estrategias de reducción (tapering) de glucocorticoides (GC) en el manejo de la polimialgia reumática (PMR) incluyen:\n\n- **Variabilidad en la práctica clínica:** La ausencia de un consenso claro lleva a diferencias significativas en cómo los médicos inician y disminuyen la dosis de GC, generando diversidad en el manejo y potencialmente en los resultados clínicos.\n\n- **Riesgo de recaídas y dependencia a largo plazo:** La falta de datos sólidos sobre cuándo y cómo hacer la reducción favorece que algunos pacientes puedan experimentar recaídas frecuentes o necesiten prolongar el tratamiento con GC, aumentando la exposición a sus efectos adversos.\n\n- **Necesidad de un manejo individualizado:** Debido a la escasez de evidencia robusta, la disminución de GC debe basarse en la respuesta clínica y en la supervisión cuidadosa, lo que puede resultar en incertidumbre y dificultad para establecer protocolos estandarizados.\n\n- **Limitación para elaborar recomendaciones sólidas:** El enfoque riguroso de revisión sistemática, combinada con la escasez de ensayos clínicos sobre este aspecto, restringe la fuerza y alcance de las recomendaciones, enfatizando el papel del juicio clínico y la opinión experta.\n\n- **Importancia de futuras investigaciones:** Esta limitación refuerza la necesidad de realizar estudios que aclaren las dosis óptimas y las mejores estrategias de tapering, para mejorar la eficacia y seguridad del tratamiento en PMR.\n\nEn resumen, la falta de consenso implica desafíos para estandarizar el tratamiento, aumenta la probabilidad de variabilidad en los resultados, y subraya la importancia de un seguimiento clínico estrecho y la investigación futura para optimizar las guías terapéuticas en PMR.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa biologic, conventional synthetic and conventional targeted) in PMR? What is the optimal strategy for using DMARDs in PMR: monotherapy versus combination therapy, early versus late introduction, and (particularly for biologics) use with or without GCs? 4. What is the minimal/optimal duration of therapy and which strategies for withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including",
            "evidence for benefit is unclear; 4) these preparations may have unforeseeable adverse effects; 5) the availability of high quality preparations is unclear; and 6) resource impact (ie, costs) is unknown. Release and implementation of the recommendations. See online supplementary file S2, on the Arthritis & Rheumatology web site at http://onlinelibrary Cost implications and conflicts of interest. Cost implications are outside the scope of these recommendations. None of the panel members disclosed any conflict of interest associated with the development of these recommendations. Discussion See online supplementary file S3 ( http://online We recognize that our recommendations are only partially supported by evidence, and that they do not cover all aspects important for the management of PMR. The group therefore unanimously agreed that the research agenda (containing the evidence gaps related to PMR management) is an important result of this project (Box 2). Due to our rigorous SLR",
            "withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including recommendations for specialist referral? How can patients be better involved in treatment decisions, and are there any decision aids? What is the role of self-management? 6. What is the value of tight control (ie, treat to target) versus conventional management strategies in PMR? 7. How should patients with long-standing disease and long-term low-dose GC therapy be managed? 8. What is the cost utility and effectiveness of DMARD use in PMR (versus GC use alone)? 9. What is the value of non-pharmacological therapies in PMR? Particularly, it is assumed but not yet demonstrated that physiotherapy may support preservation of function and reduce the risk of adverse events related to GC use. Patients may benefit from exercise by maintaining muscle mass and function as well as by fall prevention especially in the frail. What is the role of diet",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for"
        ]
    },
    {
        "pregunta": "11. What criteria were used in the 2012 classification study for assessing response to treatment in PMR?",
        "respuesta": "La información proporcionada no incluye detalles específicos sobre los criterios utilizados en el estudio de clasificación de 2012 para evaluar la respuesta al tratamiento en la polimialgia reumática (PMR).  \n\nSolo se menciona que los criterios de respuesta utilizados en dicho estudio pueden ser considerados para la evaluación clínica, pero no se describen los criterios concretos.  \n\nPor lo tanto, **no hay información suficiente disponible para detallar cuáles fueron esos criterios de respuesta al tratamiento en el estudio de clasificación de 2012 en PMR**.",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?",
            "the research agenda (containing the evidence gaps related to PMR management) is an important result of this project (Box 2). Due to our rigorous SLR approach to select high quality papers, we did not include other reviews, case reports or case series indicating possible treatment options in treatment-resistant PMR patients. For example, we found one earlier SLR reporting similar conclusions regarding the value of MTX in PMR It was beyond the scope of this recommendation project to define treatment targets in PMR. \"Clinical improvement\" was considered as the first treatment goal after the initiation of GCs, and the response criteria used in the 2012 classification criteria study may be considered The most important limitations of this project are the paucity of high quality trials (as mentioned above) and the fact that GRADE is less well developed for the assessment of rare outcomes. Consequently, the QoE for   Supported by research grants from the American College of Rheumatology",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on"
        ]
    },
    {
        "pregunta": "12. What are some common challenges in defining treatment targets in PMR?",
        "respuesta": "Algunos desafíos comunes para definir los objetivos del tratamiento en la polimialgia reumática (PMR) incluyen:\n\n- **Variabilidad en la actividad clínica y síntomas:** La presentación de la enfermedad y la respuesta al tratamiento pueden variar ampliamente entre pacientes, lo que dificulta establecer objetivos uniformes.  \n- **Falta de consenso sobre criterios de respuesta, remisión y recaída:** No existen criterios validados y ampliamente aceptados para medir con precisión la respuesta terapéutica y determinar cuándo se ha alcanzado la remisión o se ha producido una recaída.  \n- **Escasez de evidencia robusta:** La limitada cantidad de ensayos clínicos bien diseñados y datos de alta calidad sobre marcadores clínicos y laboratoriales para monitoreo restringe la definición clara de metas de tratamiento basadas en evidencia.  \n- **Necesidad de un enfoque individualizado:** Debido a la heterogeneidad de la enfermedad, el manejo y los objetivos deben adaptarse a cada paciente, considerando la actividad de la enfermedad, comorbilidades y riesgos asociados al tratamiento.  \n- **Desafíos en el balance beneficio-riesgo:** Minimizar la exposición a glucocorticoides y sus efectos adversos sin comprometer el control clínico añade complejidad para definir objetivos terapéuticos claros.\n\nEn suma, la falta de criterios estandarizados y evidencia sólida, junto con la variabilidad clínica y la necesidad de individualización, constituyen los principales retos para definir objetivos claros en el tratamiento de la PMR.",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including recommendations for specialist referral? How can patients be better involved in treatment decisions, and are there any decision aids? What is the role of self-management? 6. What is the value of tight control (ie, treat to target) versus conventional management strategies in PMR? 7. How should patients with long-standing disease and long-term low-dose GC therapy be managed? 8. What is the cost utility and effectiveness of DMARD use in PMR (versus GC use alone)? 9. What is the value of non-pharmacological therapies in PMR? Particularly, it is assumed but not yet demonstrated that physiotherapy may support preservation of function and reduce the risk of adverse events related to GC use. Patients may benefit from exercise by maintaining muscle mass and function as well as by fall prevention especially in the frail. What is the role of diet",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?"
        ]
    },
    {
        "pregunta": "13. What is the panel’s stance on the use of herbal preparations such as Yanghe and Biqi capsules in PMR?",
        "respuesta": "El panel **recomienda fuertemente en contra del uso regular de preparaciones herbales chinas como las cápsulas Yanghe y Biqi en el tratamiento de la polimialgia reumática (PMR)**. \n\nLas razones son:  \n1. El pequeño efecto observado, por ejemplo en la reducción de la velocidad de sedimentación globular (VSG), tiene una relevancia clínica mínima para los pacientes.  \n2. No existe evidencia sólida que respalde un beneficio clínico real de estas sustancias.  \n3. Ninguna de estas preparaciones está aprobada por la FDA ni la EMA.  \n4. La generalización de la evidencia disponible es incierta.  \n5. Pueden presentar efectos adversos imprevisibles.  \n6. Hay incertidumbre sobre la disponibilidad de preparaciones de alta calidad.  \n7. El impacto en recursos y costos es desconocido.\n\nPor estas razones, el panel desaconseja su uso en pacientes con PMR.",
        "contexto": [
            "(and were therefore within the scope of PICO 12); however, the panel felt the need for comment on this issue because several preparations are available which may be popular with PMR patients. The SLR identified two studies testing Chinese Yanghe herb decoction and Chinese Biqi capsules in PMR patients The group nevertheless agreed (after balancing evidence, benefit/harm, availability and resource use) to recommend strongly against the regular use of these preparations at this time for the following reasons: 1) the relevance of the small effect of Chinese Yanghe herb decoction on ESR is minimal for patients and good evidence for a clinical benefit of the substance is not available; 2) neither of the two substances is approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA); 3) the generalizability of the evidence for benefit is unclear; 4) these preparations may have unforeseeable adverse effects; 5) the availability of high quality preparations is",
            "focus on cardiovascular risk) in long-term observational studies? There are no studies investigating the value of non-pharmacological therapies (eg, physiotherapy, relaxation techniques, diets, etc.) in PMR and there is insufficient clinical experience on this issue to agree on a specific recommendation. Nevertheless, the panel agreed on recommending an individualized exercise program (see overarching principles) in view of its benefit for maintaining muscle mass and function and reducing risk of falls, especially in older persons on long-term GCs as well as in frail patients. Use of herbal preparations in PMR. The panel strongly recommends against the use of the Chinese herbal preparations Yanghe and Biqi capsules in PMR patients. There were some discussions about whether herbal preparations could be considered non-pharmacological interventions (and were therefore within the scope of PICO 12); however, the panel felt the need for comment on this issue because several preparations are",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "evidence for benefit is unclear; 4) these preparations may have unforeseeable adverse effects; 5) the availability of high quality preparations is unclear; and 6) resource impact (ie, costs) is unknown. Release and implementation of the recommendations. See online supplementary file S2, on the Arthritis & Rheumatology web site at http://onlinelibrary Cost implications and conflicts of interest. Cost implications are outside the scope of these recommendations. None of the panel members disclosed any conflict of interest associated with the development of these recommendations. Discussion See online supplementary file S3 ( http://online We recognize that our recommendations are only partially supported by evidence, and that they do not cover all aspects important for the management of PMR. The group therefore unanimously agreed that the research agenda (containing the evidence gaps related to PMR management) is an important result of this project (Box 2). Due to our rigorous SLR"
        ]
    },
    {
        "pregunta": "14. How should monitoring of disease activity and adverse events influence glucocorticoid tapering schedules in PMR?",
        "respuesta": "El monitoreo de la actividad de la enfermedad y de los eventos adversos debe guiar de manera estrecha los esquemas de reducción (tapering) de glucocorticoides (GC) en pacientes con polimialgia reumática (PMR). Según las recomendaciones clínicas actuales basadas en la revisión sistemática y consenso experto:\n\n- La disminución gradual de la dosis de GC debe realizarse cuando el paciente esté en baja actividad o en remisión clínica de la enfermedad, siempre ajustándose a la respuesta individual y los síntomas presentes.\n\n- El seguimiento estrecho durante el tapering es fundamental para detectar recaídas o brotes tempranos; si se produce una recaída, se recomienda volver a la dosis previa de GC que controlaba la enfermedad.\n\n- La vigilancia también debe considerar la aparición de efectos adversos relacionados con los glucocorticoides, orientando a realizar reducción en la medida en que el control permita minimizar la exposición.\n\n- La pauta de reducción debe ser individualizada, gradual y basada en la evaluación clínica continua, debido a la falta de datos firmes que definan el mejor esquema de tapering.\n\nEn resumen, el monitoreo frecuente y detallado de la actividad clínica y de los efectos adversos es crucial para ajustar el ritmo y la magnitud de la reducción de glucocorticoides en PMR, evitando recaídas y minimizando riesgos derivados del tratamiento prolongado.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa biologic, conventional synthetic and conventional targeted) in PMR? What is the optimal strategy for using DMARDs in PMR: monotherapy versus combination therapy, early versus late introduction, and (particularly for biologics) use with or without GCs? 4. What is the minimal/optimal duration of therapy and which strategies for withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including",
            "withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including recommendations for specialist referral? How can patients be better involved in treatment decisions, and are there any decision aids? What is the role of self-management? 6. What is the value of tight control (ie, treat to target) versus conventional management strategies in PMR? 7. How should patients with long-standing disease and long-term low-dose GC therapy be managed? 8. What is the cost utility and effectiveness of DMARD use in PMR (versus GC use alone)? 9. What is the value of non-pharmacological therapies in PMR? Particularly, it is assumed but not yet demonstrated that physiotherapy may support preservation of function and reduce the risk of adverse events related to GC use. Patients may benefit from exercise by maintaining muscle mass and function as well as by fall prevention especially in the frail. What is the role of diet",
            "this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when and how best to taper. The panel recommended that careful tapering might be considered if the patient wishes to cut back on their use of DMARDs. However, patients should be closely evaluated during any taper, and if a flare occurs, the prior regimen should be reinstituted promptly. Last, this update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?"
        ]
    },
    {
        "pregunta": "15. What is the first-line treatment recommended for patients diagnosed with polymyalgia rheumatica (PMR)?",
        "respuesta": "El tratamiento de primera línea recomendado para pacientes diagnosticados con polimialgia reumática (PMR) es el uso de **glucocorticoides (GC)** en lugar de AINEs, con excepción del posible uso a corto plazo de AINEs y/o analgésicos para el dolor relacionado con otras condiciones coexistentes (por ejemplo, osteoartritis). Esta recomendación es fuerte y está basada en la evidencia revisada por el panel.  \n\nNo se recomienda el uso de bloqueadores del TNF-alfa ni hay evidencia suficiente para recomendar otros agentes biológicos en este momento.  \n\nPor tanto, el tratamiento inicial estándar para PMR consiste en glucocorticoides en dosis adecuadas, con un seguimiento clínico estrecho para ajuste y eventual reducción.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by"
        ]
    },
    {
        "pregunta": "16. Why are NSAIDs generally discouraged as primary therapy in PMR management according to the 2015 EULAR/ACR recommendations?",
        "respuesta": "Las recomendaciones de EULAR/ACR de 2015 desaconsejan el uso de AINE como terapia primaria en el manejo de la polimialgia reumática (PMR) porque el tratamiento de primera línea debe ser con glucocorticoides, que han demostrado ser más efectivos para controlar la enfermedad. Los AINEs pueden utilizarse sólo de forma limitada y a corto plazo para el manejo del dolor relacionado con otras condiciones coexistentes (como osteoartritis), pero no se consideran adecuados como tratamiento principal para la PMR.\n\nEn resumen, los AINE no se recomiendan como terapia primaria debido a que no ofrecen un control suficiente de la inflamación ni de los síntomas principales de la PMR, a diferencia de los glucocorticoides.",
        "contexto": [
            "2015 Recommendations for the Management of Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative  Abbott  Roche  MSD  Bristol-Myers Squibb  GlaxoSmithKline  Celgene  American College of Rheumatology  Mundipharma  Merck  Amgen  Roche/Genentech  Berlin-Chemie  Mesoblast  Novartis  Centocor/Janssen  Sanofi  AbbVie  Genentech  Pfizer  Medac  European League Against Rheumatism  Servier  Ardea   October 2015     October 2015 4E3758F727ED5D273FE5CEB52C36D18A 10.1002/art.39333 Submitted for publication February 20, 2015; accepted in revised form July 13, 2015.  Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "few or no head-to-head comparison studies identified in the literature review. Thus, the quality of evidence was most often low or very low, and only occasionally moderate (Supplementary Appendix 5; http://onlinelibrary.wiley.com/ doi/10.1002/art.40726/abstract The 2018 ACR/NPF guideline for the treatment of PsA will assist patients and their health care providers in making challenging disease management decisions. More comparative data are needed to inform treatment selection. Several ongoing trials, including a trial to compare a TNFi biologic combination therapy with a TNFi biologic monotherapy and MTX monotherapy , will inform treatment decisions. We anticipate future updates to the guideline when new evidence is available.",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?"
        ]
    },
    {
        "pregunta": "17. What is the rationale behind the need for further research on existing drugs used for PMR?",
        "respuesta": "La justificación para la necesidad de realizar más investigaciones sobre los fármacos actualmente utilizados en el tratamiento de la polimialgia reumática (PMR) se basa en que:\n\n- Las recomendaciones actuales están solo parcialmente respaldadas por evidencia directa, debido a la escasez de ensayos clínicos robustos y datos de alta calidad sobre el uso de terapias farmacológicas en PMR.  \n- La revisión sistemática rigurosa llevó a limitar la evidencia considerada, excluyendo fuentes menos rigurosas, lo que resaltó la falta de estudios bien diseñados y con suficientes pacientes.  \n- Existen importantes lagunas en el conocimiento sobre dosis óptimas, estrategias de reducción de glucocorticoides, eficacia y seguridad de medicamentos modificadores de la enfermedad (DMARDs) y biológicos, y definición de criterios claros de respuesta, remisión y recaída.  \n- La diversidad en la práctica clínica y la falta de consenso en varios aspectos terapéuticos subrayan la incertidumbre actual.  \n- Por ello, el grupo enfatiza la importancia de una agenda de investigación destinada a generar evidencia sólida, desarrollar criterios validados de valoración clínica y mejorar las guías terapéuticas futuras.\n\nEn resumen, la necesidad de más investigaciones se fundamenta en la limitada y fragmentaria evidencia disponible, que restringe la fuerza y alcance de las recomendaciones actuales para el tratamiento de la PMR.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?",
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "evidence for benefit is unclear; 4) these preparations may have unforeseeable adverse effects; 5) the availability of high quality preparations is unclear; and 6) resource impact (ie, costs) is unknown. Release and implementation of the recommendations. See online supplementary file S2, on the Arthritis & Rheumatology web site at http://onlinelibrary Cost implications and conflicts of interest. Cost implications are outside the scope of these recommendations. None of the panel members disclosed any conflict of interest associated with the development of these recommendations. Discussion See online supplementary file S3 ( http://online We recognize that our recommendations are only partially supported by evidence, and that they do not cover all aspects important for the management of PMR. The group therefore unanimously agreed that the research agenda (containing the evidence gaps related to PMR management) is an important result of this project (Box 2). Due to our rigorous SLR",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for"
        ]
    },
    {
        "pregunta": "18. What is the importance of identifying clinical phenotypes or biomarkers in improving PMR treatment strategies?",
        "respuesta": "La información proporcionada no incluye datos específicos sobre la importancia de identificar fenotipos clínicos o biomarcadores para mejorar las estrategias de tratamiento en polimialgia reumática (PMR).  \n\nPor lo tanto, **no hay información suficiente disponible en esta guía para responder con precisión a la relevancia de dichos fenotipos o biomarcadores en el manejo de la PMR**.",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for"
        ]
    },
    {
        "pregunta": "19. Under what circumstances might intramuscular (i.m.) methylprednisolone be considered as an alternative to oral glucocorticoids in PMR treatment?",
        "respuesta": "La metilprednisolona intramuscular (i.m.) puede considerarse como una **alternativa condicional a los glucocorticoides orales** en el tratamiento de la polimialgia reumática (PMR) según el panel. \n\nEl panel no especifica un fenotipo clínico particular para usar preferentemente la metilprednisolona i.m., pero acuerda que en la práctica clínica puede ser considerada en casos donde se desee lograr una menor dosis acumulativa de glucocorticoides, por ejemplo en pacientes con:\n\n- Hipertensión difícil de controlar  \n- Diabetes  \n- Osteoporosis  \n- Glaucoma  \n\nAdemás, la evidencia que respalda la eficacia de la metilprednisolona i.m. proviene de un solo ensayo controlado aleatorizado, por lo que se requiere confirmación adicional de estos datos.\n\nEn resumen, la decisión entre glucocorticoides orales y metilprednisolona i.m. queda a discreción del médico tratante, considerándose la vía intramuscular especialmente en pacientes con factores de riesgo para efectos adversos por glucocorticoides orales o para reducir la exposición acumulada a éstos.",
        "contexto": [
            "The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical practice this preparation may be considered in cases where a lower cumulative GC dose is desirable, for example in female patients with difficult to control hypertension, diabetes, osteoporosis and/or glaucoma The reasons why the panel did not endorse a strong recommendation for the use of i.m. methylprednisolone are the following: 1) the efficacy of i.m. methylprednisolone is supported by a single randomized controlled trial and confirmation of these data is still necessary Recommendation 6: (PICO 8) The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on",
            "adverse events. The group further agreed that MTX may be used with oral or i.m. GC preparations even if the concomitant use of MTX and i.m. methylprednisolone has not been tested formally. The efficacy of MTX was addressed in four randomized controlled trials and one retrospective study testing the use of MTX plus oral GCs (initial prednisone doses ranging from 15 to 25 mg/day) The reasons why the panel did not support a stronger recommendation for the use of MTX in PMR are the following: 1) the total number of patients investigated in randomized trials was small (n5194) The group recognized that no recommendation can be made for the use of other non-biologic (ie, conventional synthetic and conventional targeted) DMARDs in PMR because of the lack of good evidence from PMR studies. Hydroxychloroquine was investigated by a single very low QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of",
            "recognized that 1 mg prednisone tablets are not available in all countries (making a reduction of 1 mg/4 weeks unfeasible) and that other regimens such as alternate day reductions (eg, 10/7.5 mg on alternate days, etc.) are common clinical practice Recommendation 5: (PICO 7) The panel conditionally recommends considering intramuscular (i.m.) methylprednisolone as an alternative to oral GCs. The choice between oral GCs and i.m. methylprednisolone remains at the discretion of the treating physician. In one clinical trial, i.m. methylprednisolone was applied at a dose of 120 mg every 3 weeks until week 9. At week 12, 100 mg were used and subsequently, injections were continued at monthly intervals and the dose was reduced by 20 mg every 12 weeks until week 48. Thereafter, the dose was reduced by 20 mg every 16 weeks until discontinuation The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa biologic, conventional synthetic and conventional targeted) in PMR? What is the optimal strategy for using DMARDs in PMR: monotherapy versus combination therapy, early versus late introduction, and (particularly for biologics) use with or without GCs? 4. What is the minimal/optimal duration of therapy and which strategies for withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including"
        ]
    },
    {
        "pregunta": "20. How should physicians approach the use of analgesics in PMR patients, according to the guideline?",
        "respuesta": "La guía **no emite una recomendación específica sobre el uso de analgésicos en pacientes con polimialgia reumática (PMR)**. Sin embargo, el panel reconoce que puede ser necesaria la **utilización a corto plazo de AINEs y/o analgésicos** para el manejo del dolor relacionado con condiciones concomitantes distintas a la PMR, como por ejemplo la osteoartritis.  \n\nEn resumen:  \n- No hay recomendación concreta para el uso rutinario de analgésicos en PMR.  \n- Se permite su uso limitado y temporal en caso de dolor asociado a otras patologías coexistentes.",
        "contexto": [
            "and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for analgesics. Explanation: The group recommends strongly against the use of NSAIDs compared to GCs in the treatment of PMR since the relative harm of long-term NSAID use (as mainly indicated by external evidence) outweighs the possible small benefits in PMR. No specific recommendation can be made for analgesics. On a basis of consensus, the panel recognized that the short-term use of NSAIDs and/or analgesics may be necessary in the setting of pain related to conditions other than PMR. Recommendation 2: (PICO 2) The panel strongly recommends using the minimum effective individualized duration of GC therapy in PMR patients. A more specific recommendation is not possible due to the lack of published evidence on this issue. On a basis of consensus and in accordance with the overarching principles, the group unanimously agreed to choose the",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?",
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate"
        ]
    }
]